In diabetes, rising albuminuria and reducing glomerular filtration charge are hallmarks of continual kidney illness in diabetes and improve the chance of atherosclerotic cardiovascular occasions and mortality in addition to the chance for end-stage kidney illness. For twenty years, customary of care has been controlling threat components, equivalent to glucose, blood strain, lipids, and way of life components, and particularly use of brokers blocking the renin-angiotensin system.
This has improved end result, however a big unmet want has been apparent. After many failed makes an attempt to advance the therapeutic choices, the previous few years have supplied a number of new promising remedy choices equivalent to sodium-glucose cotransporter 2 inhibitors, endothelin receptor antagonists, glucagon-like peptide 1 agonists, and nonsteroidal mineralocorticoid receptor antagonists.
The advantages and unwanted effects of those brokers exhibit the hyperlink between kidney and coronary heart; some have helpful results on each, whereas for different doubtlessly renoprotective brokers, improvement of coronary heart failure has been a limiting issue. They work on completely different pathways equivalent to hemodynamic, metabolic, inflammatory, and fibrotic targets.
We suggest that remedy could also be customized if biomarkers or physiological investigations assessing exercise in these pathways are utilized. This might doubtlessly pave the best way for precision drugs, the place remedy is optimized for maximal profit and minimal opposed outcomes. At the least it could assist prioritizing brokers for a person topic.
Low carbohydrate diets in consuming issues and kind 1 diabetes
Dietary consumption requires consideration within the remedy of each consuming issues and kind 1 diabetes (T1D) to realize optimum outcomes. Dietary administration of each situations includes encouraging all kinds of healthful meals within the context of common cultural and household traditions.
In latest instances, low carbohydrate diets have seen an increase in reputation, each in T1D and within the normal inhabitants. Low carbohydrate diets contain dietary restriction, though the extent relies on the extent of carbohydrate prescription. Though dietary restriction is a identified threat issue for consuming issues, there may be restricted literature on the affect of following a low carbohydrate food plan on the event and upkeep of consuming issues in T1D.
The purpose of this evaluation is to debate the affect of dietary restriction on the event and remedy of consuming issues and suggest issues to allow optimum well being outcomes in people with T1D, an in danger group. In an effort to obtain this, readability concerning methods that permit each flexibility in dietary consumption and facilitate wholesome consuming behaviours, while attaining glycaemic targets, are required.
Prevalence, Prevention, and Way of life Intervention of Gestational Diabetes Mellitus in China
Gestational diabetes mellitus (GDM) has change into an epidemic and has induced an incredible wholesome and financial burden in China, particularly after the “two-child coverage” put in force on October 2015.
The prevalence of GDM has continued to extend through the previous few a long time and is prone to see an extra rise sooner or later. The general public well being affect of GDM is changing into extra obvious in China and it would result in the event of continual non-communicable ailments within the long-term for each moms and their kids. Early identification of high-risk people might assist to take preventive and intervention measures to scale back the chance of GDM and opposed perinatal outcomes.
Subsequently, a give attention to prevention and intervention of GDM in China is of nice significance. Way of life interventions, together with dietary and bodily train intervention, are efficient and first-line preventive methods for GDM prevention and intervention. The GDM One-day Care Clinic established in 2011, which educates GDM sufferers on the fundamental information of GDM, dietary intervention, bodily train, weight administration, and blood glucose self-monitoring strategies, units a very good mannequin for group administration of GDM and has been carried out all through the hospitals in addition to maternal and little one well being facilities in China.
The present evaluation give attention to the prevalence, threat components, in addition to prevention and way of life intervention of GDM in China for higher understanding of the most recent epidemiology of GDM in China and assist to enhance maternal and neonatal being pregnant outcomes and promote long-term well being for ladies with GDM.
Pre-Diabetes and What It Means: The Epidemiological Proof
Prediabetes is an intermediate stage between regular glycemia and diabetes and is extremely prevalent, particularly in older age teams and overweight people. 5 completely different definitions of prediabetes are presently utilized in present observe, that are primarily based on completely different minimize factors of HbA1C, fasting glucose, and 2-h glucose.
A significant problem for the sphere is an absence of steering on when one definition may be most well-liked over one other. Dangers of main problems in individuals with prediabetes, together with diabetes, heart problems, kidney illness, and dying, additionally fluctuate relying on the prediabetes definition used. Randomized medical trials have demonstrated that way of life and pharmacologic interventions will be cost-effective, forestall diabetes, and enhance cardiovascular threat components in adults with prediabetes.
Nonetheless, the sensible implementation of way of life modification or the usage of metformin for treating prediabetes is insufficient and complex by an absence of settlement on the best way to outline the situation. Establishing consensus definitions for prediabetes needs to be a precedence and can assist inform enlargement of insurance coverage protection for way of life modification and enhance present screening and diagnostic practices.
Human IgA |
E61I021 |
EnoGene |
100ug |
EUR 411.6 |
Rabbit OVA IgA(Ovalbumin IgA) ELISA Kit |
ERB0152 |
FN Test |
96T |
EUR 681.12 |
|
Description: Method of detection: Indirect ELISA;Reacts with: Rabbit;Sensitivity: 0.234 ng/ml |
IgA Antibody |
49423-100ul |
SAB |
100ul |
EUR 399.6 |
IgA Antibody |
49423-50ul |
SAB |
50ul |
EUR 286.8 |
IgA Antibody |
45355-100ul |
SAB |
100ul |
EUR 302.4 |
IgA Antibody |
45355-50ul |
SAB |
50ul |
EUR 224.4 |
Human Adenovirus (ADV) IgA (ADV IgA) ELISA Kit |
abx364853-96tests |
Abbexa |
96 tests |
EUR 613.2 |
|
Mouse Pertussis virus IgA (PT IgA) ELISA Kit |
abx352940-96tests |
Abbexa |
96 tests |
EUR 943.2 |
|
Human Chlamydia pneumoniae IgA,Cpn IgA ELISA Kit |
201-12-2074 |
SunredBio |
96 tests |
EUR 528 |
|
Description: A quantitative ELISA kit for measuring Human in samples from biological fluids. |
Human Chlamydia pneumoniae IgA,Cpn IgA ELISA Kit |
YLA2904HU-96T |
Shanghai YL Biotech |
96T |
EUR 562.5 |
Pig Anticardiolipin Antibody IgA (aCL IgA) ELISA Kit |
abx361672-96tests |
Abbexa |
96 tests |
EUR 990 |
|
Human Anticardiolipin Antibody IgA (aCL IgA) ELISA Kit |
abx253446-96tests |
Abbexa |
96 tests |
EUR 764.4 |
|
Mouse Anticardiolipin Antibody IgA (aCL IgA) ELISA Kit |
abx254637-96tests |
Abbexa |
96 tests |
EUR 764.4 |
|
Human Anticardiolipin Antibody IgA (aCL IgA) ELISA Kit |
abx354312-96tests |
Abbexa |
96 tests |
EUR 943.2 |
|
Mouse Anticardiolipin Antibody IgA (aCL IgA) ELISA Kit |
abx354530-96tests |
Abbexa |
96 tests |
EUR 943.2 |
|
Rabbit Anticardiolipin Antibody IgA (aCL IgA) ELISA Kit |
abx363830-96tests |
Abbexa |
96 tests |
EUR 990 |
|
Monkey Anticardiolipin Antibody IgA (aCL IgA) ELISA Kit |
abx359770-96tests |
Abbexa |
96 tests |
EUR 990 |
|
Chicken Anticardiolipin Antibody IgA (aCL IgA) ELISA Kit |
abx355867-96tests |
Abbexa |
96 tests |
EUR 990 |
|
CD79a (IGA/1406) Antibody |
BNC941406-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against CD79a (IGA/1406),CF594 conjugate, Concentration: 0.1mg/mL |
CD79a (IGA/1406) Antibody |
BNC941406-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against CD79a (IGA/1406),CF594 conjugate, Concentration: 0.1mg/mL |
CD79a (IGA/1406) Antibody |
BNC801406-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against CD79a (IGA/1406),CF680 conjugate, Concentration: 0.1mg/mL |
CD79a (IGA/1406) Antibody |
BNC801406-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against CD79a (IGA/1406),CF680 conjugate, Concentration: 0.1mg/mL |
CD79a (IGA/1406) Antibody |
BNC811406-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against CD79a (IGA/1406),CF680R conjugate, Concentration: 0.1mg/mL |
CD79a (IGA/1406) Antibody |
BNC811406-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against CD79a (IGA/1406),CF680R conjugate, Concentration: 0.1mg/mL |
CD79a (IGA/1406) Antibody |
BNC701406-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against CD79a (IGA/1406),CF770 conjugate, Concentration: 0.1mg/mL |
CD79a (IGA/1406) Antibody |
BNC701406-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against CD79a (IGA/1406),CF770 conjugate, Concentration: 0.1mg/mL |
CD79a (IGA/1406) Antibody |
BNC881406-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against CD79a (IGA/1406),CF488A conjugate, Concentration: 0.1mg/mL |
CD79a (IGA/1406) Antibody |
BNC881406-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against CD79a (IGA/1406),CF488A conjugate, Concentration: 0.1mg/mL |
CD79a (IGA/1406) Antibody |
BNC051406-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against CD79a (IGA/1406),CF405M conjugate, Concentration: 0.1mg/mL |
CD79a (IGA/1406) Antibody |
BNC051406-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against CD79a (IGA/1406),CF405M conjugate, Concentration: 0.1mg/mL |
CD79a (IGA/1406) Antibody |
BNC041406-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against CD79a (IGA/1406),CF405S conjugate, Concentration: 0.1mg/mL |
CD79a (IGA/1406) Antibody |
BNC041406-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against CD79a (IGA/1406),CF405S conjugate, Concentration: 0.1mg/mL |
CD79a (IGA/1406) Antibody |
BNC401406-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against CD79a (IGA/1406),CF640R conjugate, Concentration: 0.1mg/mL |
CD79a (IGA/1406) Antibody |
BNC401406-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against CD79a (IGA/1406),CF640R conjugate, Concentration: 0.1mg/mL |
CD79a (IGA/1406) Antibody |
BNCAP1406-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against CD79a (IGA/1406),Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
CD79a (IGA/1406) Antibody |
BNCAP1406-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against CD79a (IGA/1406),Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
CD79a (IGA/1406) Antibody |
BNCA1406-250 |
Biotium |
250uL |
EUR 459.6 |
Description: Primary antibody against CD79a (IGA/1406),APC conjugate, Concentration: 0.1mg/mL |
CD79a (IGA/1406) Antibody |
BNCB1406-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against CD79a (IGA/1406),Biotin conjugate, Concentration: 0.1mg/mL |
CD79a (IGA/1406) Antibody |
BNCB1406-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against CD79a (IGA/1406),Biotin conjugate, Concentration: 0.1mg/mL |
CD79a (IGA/1406) Antibody |
BNCR1406-250 |
Biotium |
250uL |
EUR 459.6 |
Description: Primary antibody against CD79a (IGA/1406),RPE conjugate, Concentration: 0.1mg/mL |
CD79a (IGA/1406) Antibody |
BNCP1406-250 |
Biotium |
250uL |
EUR 459.6 |
Description: Primary antibody against CD79a (IGA/1406),PerCP conjugate, Concentration: 0.1mg/mL |
CD79a (IGA/1406) Antibody |
BNCH1406-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against CD79a (IGA/1406),Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
CD79a (IGA/1406) Antibody |
BNCH1406-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against CD79a (IGA/1406),Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
CD79a (IGA/1406) Antibody |
BNUB1406-100 |
Biotium |
100uL |
EUR 250.8 |
Description: Primary antibody against CD79a (IGA/1406), Concentration: 0.2mg/mL |
CD79a (IGA/1406) Antibody |
BNUB1406-500 |
Biotium |
500uL |
EUR 549.6 |
Description: Primary antibody against CD79a (IGA/1406), Concentration: 0.2mg/mL |
CD79a (IGA/1406) Antibody |
BNUM1406-50 |
Biotium |
50uL |
EUR 474 |
Description: Primary antibody against CD79a (IGA/1406), 1mg/mL |
CD79a (IGA/1406) Antibody |
BNC471406-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against CD79a (IGA/1406),CF647 conjugate, Concentration: 0.1mg/mL |
CD79a (IGA/1406) Antibody |
BNC471406-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against CD79a (IGA/1406),CF647 conjugate, Concentration: 0.1mg/mL |
CD79a (IGA/1406) Antibody |
BNC611406-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against CD79a (IGA/1406),CF660R conjugate, Concentration: 0.1mg/mL |
CD79a (IGA/1406) Antibody |
BNC611406-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against CD79a (IGA/1406),CF660R conjugate, Concentration: 0.1mg/mL |
CD79a (IGA/1406) Antibody |
BNC551406-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against CD79a (IGA/1406),CF555 conjugate, Concentration: 0.1mg/mL |
CD79a (IGA/1406) Antibody |
BNC551406-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against CD79a (IGA/1406),CF555 conjugate, Concentration: 0.1mg/mL |
CD79a (IGA/1406) Antibody |
BNC431406-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against CD79a (IGA/1406),CF543 conjugate, Concentration: 0.1mg/mL |
CD79a (IGA/1406) Antibody |
BNC431406-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against CD79a (IGA/1406),CF543 conjugate, Concentration: 0.1mg/mL |
CD79a (IGA/1406) Antibody |
BNC681406-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against CD79a (IGA/1406),CF568 conjugate, Concentration: 0.1mg/mL |
CD79a (IGA/1406) Antibody |
BNC681406-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against CD79a (IGA/1406),CF568 conjugate, Concentration: 0.1mg/mL |
CD79a (IGA/1688R) Antibody |
BNC941688-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against CD79a (IGA/1688R),CF594 conjugate, Concentration: 0.1mg/mL |
CD79a (IGA/1688R) Antibody |
BNC941688-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against CD79a (IGA/1688R),CF594 conjugate, Concentration: 0.1mg/mL |
CD79a (IGA/1688R) Antibody |
BNC801688-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against CD79a (IGA/1688R),CF680 conjugate, Concentration: 0.1mg/mL |
CD79a (IGA/1688R) Antibody |
BNC801688-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against CD79a (IGA/1688R),CF680 conjugate, Concentration: 0.1mg/mL |
CD79a (IGA/1688R) Antibody |
BNC701688-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against CD79a (IGA/1688R),CF770 conjugate, Concentration: 0.1mg/mL |
CD79a (IGA/1688R) Antibody |
BNC701688-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against CD79a (IGA/1688R),CF770 conjugate, Concentration: 0.1mg/mL |
CD79a (IGA/1688R) Antibody |
BNC811688-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against CD79a (IGA/1688R),CF680R conjugate, Concentration: 0.1mg/mL |
CD79a (IGA/1688R) Antibody |
BNC811688-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against CD79a (IGA/1688R),CF680R conjugate, Concentration: 0.1mg/mL |
CD79a (IGA/1688R) Antibody |
BNC881688-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against CD79a (IGA/1688R),CF488A conjugate, Concentration: 0.1mg/mL |
CD79a (IGA/1688R) Antibody |
BNC881688-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against CD79a (IGA/1688R),CF488A conjugate, Concentration: 0.1mg/mL |
CD79a (IGA/1688R) Antibody |
BNC051688-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against CD79a (IGA/1688R),CF405M conjugate, Concentration: 0.1mg/mL |
CD79a (IGA/1688R) Antibody |
BNC051688-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against CD79a (IGA/1688R),CF405M conjugate, Concentration: 0.1mg/mL |
CD79a (IGA/1688R) Antibody |
BNC041688-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against CD79a (IGA/1688R),CF405S conjugate, Concentration: 0.1mg/mL |
CD79a (IGA/1688R) Antibody |
BNC041688-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against CD79a (IGA/1688R),CF405S conjugate, Concentration: 0.1mg/mL |
CD79a (IGA/1688R) Antibody |
BNC401688-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against CD79a (IGA/1688R),CF640R conjugate, Concentration: 0.1mg/mL |
CD79a (IGA/1688R) Antibody |
BNC401688-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against CD79a (IGA/1688R),CF640R conjugate, Concentration: 0.1mg/mL |
CD79a (IGA/1688R) Antibody |
BNCAP1688-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against CD79a (IGA/1688R),Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
CD79a (IGA/1688R) Antibody |
BNCAP1688-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against CD79a (IGA/1688R),Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
CD79a (IGA/1688R) Antibody |
BNCA1688-250 |
Biotium |
250uL |
EUR 459.6 |
Description: Primary antibody against CD79a (IGA/1688R),APC conjugate, Concentration: 0.1mg/mL |
CD79a (IGA/1688R) Antibody |
BNCR1688-250 |
Biotium |
250uL |
EUR 459.6 |
Description: Primary antibody against CD79a (IGA/1688R),RPE conjugate, Concentration: 0.1mg/mL |
CD79a (IGA/1688R) Antibody |
BNCH1688-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against CD79a (IGA/1688R),Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
CD79a (IGA/1688R) Antibody |
BNCH1688-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against CD79a (IGA/1688R),Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
CD79a (IGA/1688R) Antibody |
BNCP1688-250 |
Biotium |
250uL |
EUR 459.6 |
Description: Primary antibody against CD79a (IGA/1688R),PerCP conjugate, Concentration: 0.1mg/mL |
CD79a (IGA/1688R) Antibody |
BNCB1688-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against CD79a (IGA/1688R),Biotin conjugate, Concentration: 0.1mg/mL |
CD79a (IGA/1688R) Antibody |
BNCB1688-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against CD79a (IGA/1688R),Biotin conjugate, Concentration: 0.1mg/mL |
CD79a (IGA/1688R) Antibody |
BNUB1688-100 |
Biotium |
100uL |
EUR 250.8 |
Description: Primary antibody against CD79a (IGA/1688R), Concentration: 0.2mg/mL |
CD79a (IGA/1688R) Antibody |
BNUB1688-500 |
Biotium |
500uL |
EUR 549.6 |
Description: Primary antibody against CD79a (IGA/1688R), Concentration: 0.2mg/mL |
CD79a (IGA/1688R) Antibody |
BNUM1688-50 |
Biotium |
50uL |
EUR 474 |
Description: Primary antibody against CD79a (IGA/1688R), 1mg/mL |
CD79a (IGA/1688R) Antibody |
BNC471688-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against CD79a (IGA/1688R),CF647 conjugate, Concentration: 0.1mg/mL |
CD79a (IGA/1688R) Antibody |
BNC471688-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against CD79a (IGA/1688R),CF647 conjugate, Concentration: 0.1mg/mL |
CD79a (IGA/1688R) Antibody |
BNC611688-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against CD79a (IGA/1688R),CF660R conjugate, Concentration: 0.1mg/mL |
CD79a (IGA/1688R) Antibody |
BNC611688-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against CD79a (IGA/1688R),CF660R conjugate, Concentration: 0.1mg/mL |
CD79a (IGA/1688R) Antibody |
BNC431688-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against CD79a (IGA/1688R),CF543 conjugate, Concentration: 0.1mg/mL |
CD79a (IGA/1688R) Antibody |
BNC431688-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against CD79a (IGA/1688R),CF543 conjugate, Concentration: 0.1mg/mL |
CD79a (IGA/1688R) Antibody |
BNC551688-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against CD79a (IGA/1688R),CF555 conjugate, Concentration: 0.1mg/mL |
CD79a (IGA/1688R) Antibody |
BNC551688-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against CD79a (IGA/1688R),CF555 conjugate, Concentration: 0.1mg/mL |
CD79a (IGA/1688R) Antibody |
BNC681688-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against CD79a (IGA/1688R),CF568 conjugate, Concentration: 0.1mg/mL |
CD79a (IGA/1688R) Antibody |
BNC681688-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against CD79a (IGA/1688R),CF568 conjugate, Concentration: 0.1mg/mL |
IgA, Fc Antibody |
abx023822-1mg |
Abbexa |
1 mg |
EUR 661.2 |
|
IgA Fc Antibody |
abx023823-1mg |
Abbexa |
1 mg |
EUR 1312.8 |
|
IgA antibody (PE) |
61R-1336 |
Fitzgerald |
100 ug |
EUR 483.6 |
Description: Rat monoclonal IgA antibody (PE) |
Human epstein-barr virus IgA,EBv IgA ELISA Kit |
201-12-1766 |
SunredBio |
96 tests |
EUR 528 |
|
Description: A quantitative ELISA kit for measuring Human in samples from biological fluids. |
Pig Anti-Myelin antibody IgA (AMA IgA) ELISA Kit |
abx360677-96tests |
Abbexa |
96 tests |
EUR 990 |
|
Human epstein-barr virus IgA(EBv IgA)ELISA Kit |
GA-E1782HM-48T |
GenAsia Biotech |
48T |
EUR 346.8 |
Human epstein-barr virus IgA(EBv IgA)ELISA Kit |
GA-E1782HM-96T |
GenAsia Biotech |
96T |
EUR 559.2 |
OVA IgA ELISA Kit| Rabbit Ovalbumin IgA ELISA Kit |
EF016908 |
Lifescience Market |
96 Tests |
EUR 826.8 |
Human Anti-Myelin antibody IgA (AMA IgA) CLIA Kit |
abx196447-96tests |
Abbexa |
96 tests |
EUR 990 |
|
FITC-Human IgA |
C050306-10ml |
Unibiotest |
10ml |
EUR 1641.6 |
Anticipated last on-line publication date for the Annual Evaluation of Public Well being, Quantity 42 is April 2021. Please see http://www.annualreviews.org/web page/journal/pubdates for revised estimates.